REFERENCES USED IN ALGORITHMS FOR THE TREATMENT OF PERSONS WITH DEPRESSION


42. Bobo WV, Shelton RC: Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues. *Neuropsychiatric Disease and Treatment* 2009, **5**:369-383.


60. Citrome L: **Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed.** *Postgraduate medicine* 2010, 122(4):39-48.

61. Citrome L: **Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?** *International journal of clinical practice* 2015, 69(9):978-997.


89. Fava M, Alpert J, Nierenberg A, Lagomasino I, Sonawalla S, Tedlow J, Worthington J, Baer L, Rosenbaum JF: Double-blind study of high-dose fluoxetine versus lithium or


110. Haslemo T, Eliasson E, Jukic MM, Ingelman-Sundberg M, Molden E: **Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients.** *British journal of clinical pharmacology* 2019, **85**(1):194-201.


*Current medical research and opinion* 2018, 34(12):2105-2112.

142. Kasper S, Pail G: Milnacipran: a unique antidepressant? 
*Neuropsychiatric Disease and Treatment* 2010, 6:23-31.


*BMC medicine* 2018, 16(1):103.


*The Medical journal of Australia* 2007, 186(3):142-144.


152. Keller MB: Issues in treatment-resistant depression. 


175. Lin XQ, Wang P, Cai WK, Xu GL, Yang M, Zhou MD, Sun M, He F, He GH: The associations between CYP2D6 metabolizer status and pharmacokinetics and


191. SwitchRx [https://www.switchrx.com/antidepressants.php/switch]


patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation. *Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology* 2006, 31(11):2505-2513.


270. Shiroma PR, Drews MS, Geske JR, Mrazek DA: **SLC6A4 polymorphisms and age of onset in late-life depression on treatment outcomes with citalopram: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report.** *The American


